NanoBio Corp., based in Ann Arbor, Mich., has been awarded a patent for the technology behind its anti-infection and dermatology drugs.
"We are very pleased with this patent award in that the new claims circumscribe all of NanoBio's anti-infective and dermatological products, as well as our intranasal and intramuscular vaccine adjuvants," says company CEO and founder James R. Baker, Jr., MD.
"The patent, NanoBio's sixth, comes after the firm struck a multimillion-dollar licensing deal with United Kingdom-based pharmaceutical giant GlaxoSmithKline to license NanoBio's cold sore treatment still in clinical development," writes AnnArbor.com's Nathan Bomey.
"The company has several drugs under development, all based on its Nanostat technology platform, which delivers drugs through the skin or nasal passages rather than using needles," writes MedCity News' Brandon Glenn.
Addthis
Ask
Blinklist
del.icio.us
Digg
Fark
Facebook
Google
Lycos
Ma.gnolia
Mr Wong
Netscape
Netvousz
Newsvine
Reddit
StumbleUpon
Slashdot
Tailrank
Technorati
Wink
Yahoo
Vote for NanoBio Patents Drug Tech:
|
Rating: 10.00 out of 1 vote(s) cast.
|
| RSS |  See all blog subscribe options |
 What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |
